Cell penetrating peptides functionalized gambogic acid-nanostructured lipid carrier for cancer treatment

Figures & data

Table 1. Particle size, polydispersity index, zeta potential and entrapment efficiency of GA-NLC and CPP-modified GA-NLC.

Groups	Particle size (nm)	PDI	Zeta potential (mV)	Entrapment efficiency (%)
GA-NLC	20.96 ± 1.13	0.23 ± 0.08	−5.86 ± 0.64	99.46 ± 0.43
GA-NLC-RGE	22.13 ± 0.79	0.19 ± 0.04	−3.50 ± 2.01
GA-NLC-cRGD	21.01 ± 0.54	0.20 ± 0.09	−4.01 ± 0.67
GA-NLC-RGE/cRGD	25.81 ± 0.66	0.24 ± 0.06	−1.98 ± 1.01

GA: gambogic acid; NLC: nanostructured lipid carrier; CPP: cell penetrating peptide.

Figure 1. Cytotoxicity of GA-sol, GA-NLC, and peptide-modified GA-NLC in MDA-MB-231 cell.

Figure 2. (A) Fluorescence intensity of different Cou6-loaded formulation in MDA-MB-231 cells. (B) Cellular uptake of Cou-6 formulations at different time intervals. a: Cou-6-NLC-RGE, b: Cou-6-NLC-cRGD, c: Cou-6-NLC-RGE/cRGD, d: Cou-6-NLC and e: Cou-6-Sol.

Figure 3. The in vivo imaging of the nude mouse after administration of DiR-loaded formulations. A: DiR-NLC-RGE, B: DiR-NLC-cRGD, C: DiR-NLC-RGE/cRGD, D: DiR-NLC.

Figure 4. (A) Change in the volume of tumor over the course of treatment. (B) The volume of excised tumor tissue. A: Saline, B: cisplatin, C: GA-Sol, D: GA-NLC, E: GA-NLC-RGE, F: GA-NLC-cRGD and G: GA-NLC-RGE/cRGD.

Figure 5. HE staining of major organs and tumor tissue. (A) Saline, (B) cisplatin, (C) GA-Sol, (D) GA-NLC, (E) GA-NLC-RGE, (F) GA-NLC-cRGD and (G) GA-NLC-RGE/cRGD.